How Certain Antidepressants May Help Long COVID: a simple, plain language explanation of the biological mechanisms.

As someone who has suffered with COVID, and truly at times feel as though I am still suffering with Long COVID this is exciting news.

Here’s the simplest way to explain it:

Certain antidepressants don’t just affect mood—they also calm inflammation, improve serotonin balance, reduce micro clots, and help cells recover from stress. These combined effects may ease Long COVID symptoms like fatigue and brain fog.

How Antidepressants Might Help with Long COVID

Long COVID can leave people feeling tired, foggy, and achy for months. Some antidepressants—especially fluvoxamine—may help because they do more than lift mood. They also calm inflammation, improve blood flow, and help the body’s cells recover.

1. Calming the immune system

Long COVID can make the immune system act like a fire that won’t go out. Certain antidepressants switch on a “fire chief” receptor (called sigma‑1) that tells the immune system to cool down. When that happens:

• Inflammation drops

• The body stops sending out “alarm” signals

• Fatigue, brain fog, and body aches can ease

  
  

 2. Restoring serotonin balance

COVID can lower serotonin, the chemical that helps control mood, sleep, and energy. It happens because the virus:

• Damages gut cells that make serotonin

• Triggers inflammation that blocks serotonin production

• Leaves behind fragments that keep the immune system on alert

Antidepressants help the brain reuse the serotonin that’s left, which can improve energy, sleep, and focus.

3. Improving blood flow

Some Long COVID symptoms come from tiny blood clots that block oxygen. Certain antidepressants make platelets less sticky, helping blood flow more freely. This may reduce fatigue, head pressure, and exercise intolerance.

4. Helping cells recover

The same sigma‑1 receptor also helps cells clean up damage and make energy more efficiently. That can mean:

• More stamina

• Less crash after activity

• Sharper thinking

  
  

 5. Blocking a harmful pathway

COVID can turn on a “bad” enzyme that makes fatty molecules called ceramides, which damage cells and increase inflammation. Some antidepressants shut down this pathway, protecting cells and helping serotonin work better.

🌟 In short

Certain antidepressants don’t just help mood—they also calm inflammation, improve serotonin balance, reduce micro clots, and help cells heal. Together, these effects may ease Long COVID symptoms like fatigue and brain fog.

 REFERENCES:

Farahani, R. H., Ajam, A., & Naeini, A. R. (2023). Effect of fluvoxamine on preventing neuropsychiatric symptoms of post‑COVID syndrome in mild to moderate patients: A randomized placebo‑controlled double‑blind clinical trial. BMC Infectious Diseases, 23, 197. https://doi.org/10.1186/s12879-023-08152-3 (doi.org in Bing)

Hashimoto, K. (2023). Overview of the potential use of fluvoxamine for COVID‑19 and long COVID. Discovery Mental Health, 3(1), 9. https://doi.org/10.1007/s44192-023-00036-8 (doi.org in Bing)

Hoertel, N., Sánchez‑Rico, M., Vernet, R., et al. (2021). Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID‑19: Results from an observational study. Molecular Psychiatry, 26, 5199–5212. https://doi.org/10.1038/s41380-021-01021-4 (doi.org in Bing)

Mazza, M. G., Zanardi, R., Palladini, M., et al. (2022). Rapid response to selective serotonin reuptake inhibitors in post‑COVID depression. European Neuropsychopharmacology, 54, 1–6. https://doi.org/10.1016/j.euroneuro.2021.12.005 (doi.org in Bing)

Nykamp, M. J., Zorumski, C. F., Reiersen, A. M., et al. (2022). Opportunities for drug repurposing of serotonin reuptake inhibitors: Potential uses in inflammation, infection, cancer, neuroprotection, and Alzheimer’s disease prevention. Pharmacopsychiatry, 55(1), 24–29. https://doi.org/10.1055/a-1660-4604 (doi.org in Bing)

Rivas‑Vázquez, R. A., Carrazana, E. J., Rivas‑Vázquez, E. V., et al. (2024). Growing evidence for potential use of antidepressants for long COVID. Primary Care Companion for CNS Disorders, 26(3), 23lr03690. https://doi.org/10.4088/PCC.23lr03690

Rus, C. P., de Vries, B. E. K., de Vries, I. E. J., et al. (2023). Treatment of 95 post‑COVID patients with SSRIs. Scientific Reports, 13, 18599. https://doi.org/10.1038/s41598-023-45643-1 (doi.org in Bing)

Wong, C. K., Lam, C. W. K., Wu, A. K. L., et al. (2023). Autoantibodies in patients with long COVID. Cell, 186(21), 4851–4867. https://doi.org/10.1016/j.cell.2023.09.020 (doi.org in Bing)

rncyndi2000

Assessed and Endorsed by the MedReport Medical Review Board